BridgeBio Pharma, Inc.

Key metrics

Financial performance

Over the last 6 fiscal years BridgeBio Pharma, Inc.'s revenue grew from $40.56M to $502.08M, a compound annual growth rate of 52.1%.

Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.

Key statistics

Latest filings

Browse the full filing history (768 filings)

Recent press releases

• BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH12026-05-12

  _\- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1_

• Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure2026-05-11

  _-Acoramidis increased sTTR early and significantly reduced intra-individual sTTR variability versus placebo (p<0.001), which is associated with reduced ACM, further reinforcing its differentiated profile in ATTR-CM_

• BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)2026-05-08

  BridgeBio exists to develop transformative medicines for genetic conditions. Millions of people worldwide living with genetic conditions lack treatment options, often because drug development for small patient populations can be commercially challenging. We aim to bridge the gap between advancements in genetic science and meaningful medicines for underserved patient populations. Our decentralized, hub-and-spoke model is designed for speed, precision, and scalability. Autonomous and empowered teams focus on individual conditions, while a central hub provides the clinical, regulatory, and commercial capabilities needed to bring innovation to market. For more information, visit **bridgebio.com** and follow us on **LinkedIn**, **X**, **Facebook**, **Instagram**, **YouTube**, and **TikTok** **.**

• BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates2026-05-07

  _$194.5 million in total first quarter revenues, comprised of $180.6 million of U.S. Attruby® net product revenue, with strong prescribing growth and patient persistence driving continued commercial momentum_

• BridgeBio to Participate in May and June Investor Conferences2026-05-06

  **BofA Securities Health Care Conference 2026, Las Vegas, NV:** Tuesday, May 12 at 2:20 pm PDT

Similar companies

The largest companies sharing BridgeBio Pharma, Inc.'s SEC industry classification (pharmaceutical preparations).